UPDATE: Auriga Raises Price Target on the Medicines Company to $25

by John Harris, Benzinga Staff Writer

February 23, 2012 11:14 AM | 17 seconds read | Make a Comment

According to Auriga, the Medicines Company

MDCO

price target is raised to $25. Auriga said that MDCO had a strong quarter due to high demand of Angiomax, with results handily beating consensus on both revenue and EPS. “We reiterate BUY and raise price target to $25.00.” The Medicines Company closed yesterday at $22.28.

Market News and Data brought to you by Benzinga APIs

Posted In: Analyst Color Price Target Analyst Ratings Auriga

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!